Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
170 patients (estimated)
Sponsors
Chordia Therapeutics, Inc.
Collaborators
Theradex
Tags
CLK Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1501
NCT Identifier
NCT05732103

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.